Chinese Journal of Pharmacovigilance ›› 2022, Vol. 19 ›› Issue (8): 919-920.
DOI: 10.19803/j.1672-8629.2022.08.21

Previous Articles     Next Articles

Pharmacovigilance of propacetamol hydrochloride for injection

ZHANG Tao1, ZHAO Jing1, LI Jing1, LI Maoxing1, FENG Xia2, LIN Tong3*   

  1. 1Department of Clinical Pharmacy, 940th Hospital of Joint Logistics Support Force of PLA, Lanzhou Gansu 730050, China;
    2Department of Nurse, 940th Hospital of Joint Logistics Support Force of PLA, Lanzhou Gansu 730050, China;
    3Department of Medicine, 940th Hospital of Joint Logistics Support Force of PLA, Lanzhou Gansu 730050, China
  • Received:2020-12-01 Online:2022-08-15 Published:2022-08-15

Abstract: Objective To provide pharmacovigilance of propacetamol hydrochloride for injection by 2 cases of severe adverse drug reactions. Methods A retrospective analysis was performed on 2 cases of severe bilateral upper limb venous thrombosis caused by propacetamol hydrochloride for injection. Results The heavy concentrations, fast intravenous infusion and long course of treatment of propacetamol hydrochloride for injection lead to patient severe bilateral upper limb venous thrombosis. Conclusion Patients' allergy history should be carefully asked before any treatment of drugs with a reasonable dose and a reasonable route. Clinical using of propacetamol hydrochloride for injection should be strictly followed its instructions. The solvent should be NS 100ml and the infusion time is 15 minutes. Long-term and off-label indications should be forbidden.

Key words: pharmacovigilance, propacetamol hydrochloride, adverse drug reactions, vein thrombosis

CLC Number: